Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D
- PMID: 7933081
- PMCID: PMC237136
- DOI: 10.1128/JVI.68.11.6994-7000.1994
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D
Abstract
Human monoclonal antibody 447-52D binds to the V3 determinant of the human immunodeficiency virus type 1 (HIV-1) gp120 external glycoprotein. Its binding requires the expression of the GPxR sequence at the center of the V3 domain. HIV-1 variants that are adapted to replication in T-lymphoid cell lines and express this sequence motif are efficiently neutralized by the antibody (M. K. Gorny, A. J. Conley, S. Karwowska, A. Buchbinder, J.-Y. Xu, E. A. Emini, S. Koenig, and S. Zolla-Pazner, J. Virol. 66:7538-7542, 1992). In the present study, the antiviral activity of 447-52D was further defined with regard to its ability to mediate neutralization of primary HIV-1 clinical isolates. Again, the antibody was found to potently neutralize those isolates that expressed the binding sequence. We confirmed that this determinant is commonly expressed by virus isolates belonging to the subtype (clade) B sequence classification. As such, 447-52D may be useful for prophylactic and immunotherapeutic intervention. In addition, the study demonstrated that neutralization of primary HIV-1 isolates is possible if mediated by an appropriate antibody.
Similar articles
-
The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.AIDS Res Hum Retroviruses. 2004 Nov;20(11):1254-8. doi: 10.1089/aid.2004.20.1254. AIDS Res Hum Retroviruses. 2004. PMID: 15588347
-
Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.Biochem J. 2006 Nov 1;399(3):483-91. doi: 10.1042/BJ20060588. Biochem J. 2006. PMID: 16827663 Free PMC article.
-
Identification of HIV vaccine candidate peptides by screening random phage epitope libraries.Virology. 1993 Apr;193(2):709-16. doi: 10.1006/viro.1993.1179. Virology. 1993. PMID: 7681612
-
The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.J Virol. 2004 Mar;78(5):2394-404. doi: 10.1128/jvi.78.5.2394-2404.2004. J Virol. 2004. PMID: 14963135 Free PMC article.
-
Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.J Virol. 1992 Mar;66(3):1823-31. doi: 10.1128/JVI.66.3.1823-1831.1992. J Virol. 1992. PMID: 1637373 Free PMC article.
Cited by
-
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.J Virol. 2010 Feb;84(3):1439-52. doi: 10.1128/JVI.02108-09. Epub 2009 Nov 25. J Virol. 2010. PMID: 19939925 Free PMC article.
-
Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes.PLoS One. 2010 Dec 29;5(12):e15994. doi: 10.1371/journal.pone.0015994. PLoS One. 2010. PMID: 21209919 Free PMC article.
-
A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120.J Virol. 2008 Jul;82(13):6359-68. doi: 10.1128/JVI.00293-08. Epub 2008 Apr 23. J Virol. 2008. PMID: 18434393 Free PMC article.
-
Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies.PLoS One. 2014 Jan 23;9(1):e86905. doi: 10.1371/journal.pone.0086905. eCollection 2014. PLoS One. 2014. PMID: 24466285 Free PMC article.
-
The efficacy of T cell-mediated immune responses is reduced by the envelope protein of the chimeric HIV-1/SIV-KB9 virus in vivo.J Immunol. 2008 Oct 15;181(8):5510-21. doi: 10.4049/jimmunol.181.8.5510. J Immunol. 2008. PMID: 18832708 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials